Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie
 
> Floxuridine [50-91-9]

Floxuridine [50-91-9]

Drucken Drucken
Melden Sie sich an

Katalog-Nummer HY-B0097-200mg

Size : 200mg

Marke : MedChemExpress

Weitere Informationen anfordern

Contact local distributor :


Telefonnummer : +1 850 650 7790

Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis. Floxuridine has antiviral effects against HSV and CMV.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Floxuridine Chemische Struktur

Floxuridine Chemische Struktur

CAS. Nr. : 50-91-9

This product is a controlled substance and not for sale in your territory.

Based on 7 publication(s) in Google Scholar

Other Forms of Floxuridine:

  • Floxuridine (Standard) Angebot einholen

Alle HSV Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen
HSV-1 HSV-2 HSV
Beschreibung

Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis[1][2]. Floxuridine has antiviral effects against HSV and CMV[3].

IC50 & Target[1][2][3]

DNA synthesis

 

Bacterial

 

HSV

 

CMV

 

In Vitro

Floxuridine (0-25 μM; 4-24 hours) is affectd by inhibitors of PARP and its sensitivity of ovarian cancer cells is enhanced. Co-exposed to FdUrd and the PARP inhibitor markedly increases killing cell numbers when its compare to treatment alone in ovarian cancer cells[1].
Floxuridine (300 μM; 4-24 hours) increases p-Chk1 and p-Chk2 in ovarian cancer cell lines. It may induce DNA damage and activate the ATM and ATR checkpoint signaling pathways[1].
Floxuridine (0-2.5 μM; 24 hours) causes a G1/S-phase arrest and following removal of the FdUrd, the G1/S-phase-arrested cells moved synchronously through S phase and into G2/M[1].
Floxuridine is also a very potent inhibitor of staphylococcal growth (MIC, 0.025–0.00313 μM)[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Floxuridine Related Antibodies

Cell Viability Assay[1]

Cell Line: Ovarian cancer cells
Concentration: 0-25 μM
Incubation Time: 4, 8, 24 hours
Result: Was potentiated the sensitivity by  PARP inhibitors.

Western Blot Analysis[1]

Cell Line: OVCAR-8 and SKOV3ip cells
Concentration: 300 μM
Incubation Time: 4, 8, 24 hours
Result: Induced phosphorylation of Chk1 and Chk2 in two ovarian cancer cell lines

Cell Cycle Analysis[1]

Cell Line: A2780, SKOV3ip, OVCAR-5, and OVCAR-3 ovarian cancer cells
Concentration: 0.5, 1.0, 1.5, 2.0, and 2.5 μM
Incubation Time: 24 hours
Result: Induced cell arrest at G1/S-phase period.
In Vivo

Floxuridine (intraperitoneal injection; 0.5-1.25 mg/kg; once per day for 7 days or single dose) is sufficient to show statistically significant protection against S. aureus infection at 0.5 mg/kg for 7 days. In addition, 1.25 mg/kg single administration of the compound shows statistically significant protection against S. aureus infection[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice injected with S. aureus[2]
Dosage: 0.5-1.25 mg/kg
Administration: once per day for 7 days or single dose
Result: Was a very potent inhibitor for S. aureus infection in vivo.
Klinische Studie
Molekulargewicht

246.19

Formel

C9H11FN2O5
CAS. Nr.

50-91-9
Appearance

Solid

Color

White to off-white

SMILES

OC[C@@H]1[C@@H](O)C[C@H](N2C(NC(C(F)=C2)=O)=O)O1
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Lösungsmittel & Löslichkeit
In Vitro: 

DMSO : 125 mg/mL (507.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : ≥ 50 mg/mL (203.10 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.0619 mL 20.3095 mL 40.6190 mL
5 mM 0.8124 mL 4.0619 mL 8.1238 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molaritätsrechner

  • Verdünnungsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (8.45 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (8.45 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (406.19 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Reinheit & Dokumentation

Purity: 99.95%

COA (252 KB) HNMR (260 KB) LCMS (267 KB)

Handling Instructions (2659 KB)
Verweise

  • [1]. Huehls AM, et al. Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.Cancer Res. 2011 Jul 15;71(14):4944-54.  [Content Brief]

    [2]. Yeo WS, et al. The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus.Sci Rep.  2018 Feb 6;8(1):2521.  [Content Brief]

    [3]. Langman J, et al. Floxuridine and its influence on postnatal cerebellar development. Pediatr Res. 1972 Oct;6(10):758-64.  [Content Brief]

  • [1]. Huehls AM, et al. Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.Cancer Res. 2011 Jul 15;71(14):4944-54.

    [2]. Yeo WS, et al. The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus.Sci Rep.  2018 Feb 6;8(1):2521.

    [3]. Langman J, et al. Floxuridine and its influence on postnatal cerebellar development. Pediatr Res. 1972 Oct;6(10):758-64.

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 4.0619 mL 20.3095 mL 40.6190 mL 101.5476 mL
5 mM 0.8124 mL 4.0619 mL 8.1238 mL 20.3095 mL
10 mM 0.4062 mL 2.0310 mL 4.0619 mL 10.1548 mL
15 mM 0.2708 mL 1.3540 mL 2.7079 mL 6.7698 mL
20 mM 0.2031 mL 1.0155 mL 2.0310 mL 5.0774 mL
25 mM 0.1625 mL 0.8124 mL 1.6248 mL 4.0619 mL
30 mM 0.1354 mL 0.6770 mL 1.3540 mL 3.3849 mL
40 mM 0.1015 mL 0.5077 mL 1.0155 mL 2.5387 mL
50 mM 0.0812 mL 0.4062 mL 0.8124 mL 2.0310 mL
60 mM 0.0677 mL 0.3385 mL 0.6770 mL 1.6925 mL
80 mM 0.0508 mL 0.2539 mL 0.5077 mL 1.2693 mL
100 mM 0.0406 mL 0.2031 mL 0.4062 mL 1.0155 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Floxuridine Related Classifications

  • Cell Cycle/DNA Damage Anti-infection Apoptosis
  • Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Bacterial CMV HSV Apoptosis
Help & FAQs

Keywords:

Floxuridine50-91-95-Fluorouracil 2'-deoxyribosideNucleoside Antimetabolite/AnalogDNA/RNA SynthesisBacterialCMVHSVApoptosisCytomegalovirusHerpes simplex virusS. aureuspolymeraseOncologyAntimetaboliteOvariancancercellsOVCAR-8SKOV3ipInhibitorinhibitorinhibit

Sie könnten auch an folgenden Produkten interessiert sein:



Katalog-Nummer
Beschreibung
Cond.
Preis zzgl. MwSt.
HY-B0097-500mg
Floxuridine [50-91-9]
 500mg 
HY-B0522-1g
Ampicillin [69-53-4]
 1g